All In Biotech

Drug Trial Radar · NCT01436175

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant

Last checked: Nov 19, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,570

Actual

Start

Feb 27, 2012

Primary completion

Mar 27, 2014

Study completion Mar 27, 2014

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous double-blind MDD augmentation study using SPD489.

Conditions

  • Major Depressive Disorder

Interventions

  • SPD489 (Lisdexamfetamine dimesylate) + AntidepressantDrug

    SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Week 5 up to Week 52/Early Termination(ET)
  2. Change From Baseline in Systolic Blood Pressure at Week 52Time frame: Baseline, Week 52/ET
  3. Change From Baseline in Diastolic Blood Pressure at Week 52Time frame: Baseline, Week 52/ET
  4. Change From Baseline in Pulse Rate at Week 52Time frame: Baseline, Week 52/ET

Locations

212 sites in 14 countries. Site status is shown where the registry gives one.

  • Birmingham Research Group

    Birmingham, Alabama

  • ResearchOne, Inc.

    Scottsdale, Arizona

  • Arkansas Psychiatric Clinical Research Trials, P.A.

    Little Rock, Arkansas

  • South Coast Clinical Trials, Inc.

    Anaheim, California

  • American Neuropsychiatric Research, Inc.

    Carson, California

  • Catalina Research Institute, LLC

    Chino, California

  • Shanti Clinical Trials

    Colton, California

  • ATP Clinical Research

    Costa Mesa, California

  • Clinical Innovation, Inc.

    Costa Mesa, California

  • Diligent Clinical Trials

    Downey, California

  • Synergy Clinical Research Center of Escondido

    Escondido, California

  • Collaborative Neuroscience Network, Inc.

    Garden Grove, California

  • UC, Irvine Child Development Center

    Irvine, California

  • Irvine Center For Clinical Research

    Irvine, California

  • Omega Clinical Trials, LLC

    La Habra, California

  • Semel Institute for Neuroscience & Human Behavior at UCLA

    Los Angeles, California

  • Pacific Research Partners

    Oakland, California

  • North County Clinical Research

    Oceanside, California

  • Pasadena Research Institute, LLC

    Pasadena, California

  • Anderson Clinical Research

    Redlands, California

  • BreakThrough Clinical Trials, LLC

    San Bernardino, California

  • Affiliated Research Institute

    San Diego, California

  • PCSD - Feighner Research

    San Diego, California

  • Clinical Innovations, Inc.

    San Diego, California

  • Sharp Mesa Vista Hospital

    San Diego, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Neuropsychiatric Center of Orange County

    Santa Ana, California

  • Caliifornia Neuroscience Research Medical Group

    Sherman Oaks, California

  • MCB Clinical Research Centers

    Colorado Springs, Colorado

  • Western Affiliated Research Institute

    Denver, Colorado

  • Connecticut Clinical Research

    Cromwell, Connecticut

  • Geriatric and Adult Psychiatry, LLC

    Hamden, Connecticut

  • Institute of Living - Hartford Hospital

    Hartford, Connecticut

  • The Hospital of Central Connecticut

    New Britain, Connecticut

  • Florida Clinical Research Center, LLC

    Bradenton, Florida

  • CNS Clinical Research Group

    Coral Springs, Florida

  • Gulfcoast Clinical Research Center

    Fort Myers, Florida

  • Emerald Coast Mood & Memory, PA

    Fort Walton Beach, Florida

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

Showing 40 of 212 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.